Shandong Aonai Biopharmaceutical Co., Ltd., a science-driven pet supplement manufacturer and pet supplement supplier based in Linyi City, Shandong Province, China, has achieved a new milestone in its domestic intellectual property portfolio: the invention patent application for "A Method for Producing a Dispersed Submicron Emulsion Based on Lemon Extract" (application number 202210953539.3) has passed the preliminary examination conducted by the China National Intellectual Property Administration (CNIPA), with the examination approval notice issued on October 10, 2022. The application was filed on August 10, 2022, and the passing of preliminary examination confirms that the application complies with the requirements of Article 44 of the Implementing Regulations of the Patent Law, allowing it to proceed toward publication.
The invention relates to a production method for a dispersed submicron emulsion based on lemon extract ― an advanced delivery system that encapsulates active ingredients in ultra-fine emulsion droplets at the submicron scale. This technology addresses a fundamental challenge in pet nutrition formulation: many functional ingredients, particularly oil-soluble compounds, suffer from poor stability, low bioavailability, and uneven dispersion when added to finished products.
In a submicron emulsion, the active phase is broken into droplets typically ranging from hundreds of nanometers to a few microns, dramatically increasing the specific surface area of the ingredients. The production method covered by the application controls the emulsification process ― including energy input, emulsifier selection, and droplet size distribution ― to achieve a stable, uniformly dispersed system suitable for commercial manufacturing. This approach is especially valuable for oil-soluble actives such as fish oil and lipid-soluble vitamins, as well as for protecting sensitive components from oxidative degradation during processing and storage.
Key technical advantages of the submicron emulsion approach include:Enhanced stability: the emulsion structure protects active ingredients from oxidation, light, and environmental degradation, extending product shelf life;
Improved bioavailability: submicron droplet size significantly increases the surface area available for absorption, helping functional ingredients deliver their intended effects;
Uniform dispersion: consistent distribution of active ingredients throughout the product ensures every dose delivers consistent nutrition;
Production scalability: the method is designed for industrial manufacturing, supporting large-scale production of high-quality formulations.
Lemon extract is valued in pet nutrition and health products for its natural antioxidant properties and vitamin C content, supporting immune function and overall wellness. The combination of lemon extract with submicron emulsion technology in this invention reflects the company's ongoing investment in functional ingredient delivery ― a core competency that benefits its entire product portfolio, including dog joint supplements, dog multivitamins, and digestive & probiotic supplements.
The emulsion technology patent application joins a rapidly expanding IP portfolio that spans both domestic and international protection:
Technology
Protection Status
Dr.kalan compound probiotic
Dutch invention patent No. 4000956
Granted (July 30, 2026)
Gastric acid-resistant Dr.kalanmcollagen peptide
Dutch application NL 4000998
Positive EPO written opinion (claims 1‒7 novel, inventive, industrially applicable)Technology
Protection Status
Dispersed submicron emulsion based on lemon extract
Chinese application 202210953539.3
Preliminary examination passed (October 10, 2022)
This portfolio covers three complementary layers of pet health technology: gut health (probiotics), bone & joint and skin & coat health (collagen peptides), and functional ingredient delivery systems (submicron emulsion) ― giving the company a well-rounded foundation for product innovation and differentiation.
For brands and distributors, the company's expanding patent portfolio translates into tangible commercial value:
Technology-backed formulations: products developed with these patented technologies carry verifiable technical credentials, strengthening claims and marketing messages;
Custom development capability: with proprietary delivery system technology, the company can support custom formula development for complex formulations that require enhanced stability and bioavailability;
Flexible cooperation models: the full Dr.kalan product line is available through OEM/ODM, private label, and bulk supply programs, backed by factory-direct production and full-chain quality control;
Future-ready R&D pipeline: the company's ongoing investment in delivery systems and functional ingredients positions its partners to stay ahead of market trends.
Shandong Aonai Biopharmaceutical Co., Ltd. is a science-driven pet health enterprise located in the Wenshui Industrial Park, Pingyi County, Linyi City, Shandong Province, China. The company integrates R&D, production, and sales, with a product portfolio spanning dog joint supplements, dog multivitamins, dental care products, and digestive & probiotic supplements under its Dr.kalan brand. As an experienced pet supplement manufacturer and pet supplement supplier, the company offers flexible OEM/ODM, private label, and custom formula services to brands and distributors worldwide. Its quality assurance system is backed by an FSPCA PCQI-certified R&D team, and the company holds multiple international invention patents and patent applications covering its Dr.kalan compound probiotics and gastric acid-resistant collagen peptides. Committed to "quality first, safety first, technology driven," Shandong Aonai is dedicated to delivering safe, scientific, and premium pet health products to pets and pet parents around the world.
The preliminary examination approval of the emulsion patent application is another step in the company's journey of technological innovation, strengthening its ability to deliver stable, effective, and science-backed pet nutrition solutions to global partners.
EN
